Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 50 of 62 results for neuropathic pain

  1. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

    This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.

  2. Chronic and neuropathic pain

    All NICE products on chronic and neuropathic pain. Includes any guidance, advice and quality standards.

  3. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)

    Evidence-based recommendations on spinal cord stimulation for chronic pain of neuropathic or ischaemic origin in adults.

  4. Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain (MTG41)

    Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.

  5. Medicines Optimisation for Neuropathic Pain

    the team sought to improve quality and efficiency of prescribing for neuropathic pain, whilst reducing variation in prescribing...

  6. Percutaneous electrical nerve stimulation for refractory neuropathic pain (IPG450)

    Evidence-based recommendations on percutaneous electrical nerve stimulation for refractory neuropathic pain. This involves inserting electrode needles underneath the skin connected to a stimulator device.

  7. Transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain (IPG632)

    Evidence-based recommendations on transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain in adults. This involves delivering focused ultrasound to a small part of the brain (in the thalamus) responsible for transmitting pain signals to destroy it.

  8. Spinal injury: assessment and initial management (NG41)

    This guideline covers the assessment and early management of spinal column and spinal cord injury in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It covers traumatic injuries to the spine but does not cover spinal injury caused by a disease. It aims to reduce death and disability by improving the quality of emergency and urgent care.

  9. Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain (MIB238)

    NICE has developed a medtech innovation briefing (MIB) on Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain .

  10. Low back pain and sciatica in over 16s: assessment and management (NG59)

    This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.

  11. Endometriosis: diagnosis and management (NG73)

    This guideline covers diagnosing and managing endometriosis. It aims to raise awareness of the symptoms of endometriosis, and to provide clear advice on what action to take when women with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.

  12. Myeloma: diagnosis and management (NG35)

    This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

  13. Pancreatitis (NG104)

    This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.

  14. Cannabis-based medicinal products (NG144)

    This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

  15. Low-level laser therapy (photobiomodulation) for oral neuropathic pain

    Register an interest in this interventional procedure   ...

  16. Potential for dependence associated with pharmacological drugs for neuropathic pain:- Is there a potential for dependence associated with pharmacological agents for neuropathic pain?

    pharmacological drugs for neuropathic pain:- Is there a potential for dependence associated with pharmacological agents for...

  17. Neuropathic pain relief:- Does early treatment with a centrally acting analgesic (for example pregabalin) reduce the frequency or severity of neuropathic pain in people with spinal cord injury?

    Recommendation ID NG41/1 Question Neuropathic pain relief:- Does early treatment with a centrally acting analgesic (for example...

  18. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)

    This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.

  19. Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    Question Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness, cost effectiveness...

  20. Does early intervention to treat neuropathic pain reduce the likelihood of chronic pain?

    Question Does early intervention to treat neuropathic pain reduce the likelihood of chronic pain? Any explanatory notes(if...

  21. Is there a potential for dependence associated with pharmacological agents for neuropathic pain?

    potential for dependence associated with pharmacological agents for neuropathic pain? Any explanatory notes(if applicable) There has...

  22. How should the symptomatic treatment of neuropathic pain relate to its cause?

    CG173/7 Question How should the symptomatic treatment of neuropathic pain relate to its cause? Any explanatory notes(if applicable)

  23. What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain?

    and quality of life in neuropathic pain? Any explanatory notes(if applicable) Pharmacological agents for neuropathic pain...

  24. What are the key factors, including additional care and support, that influence participation* and quality of life in people with neuropathic pain?

    support, that influence participation* and quality of life in people with neuropathic pain? Any explanatory notes(if applicable) * The...

  25. What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    pharmacological monotherapy compared with combination therapy for treating neuropathic pain? Any explanatory notes(if applicable) Why...

  26. Factors affecting participation and quality of life:- What are the key factors, including additional care and support, that influence participation and quality of life in people with neuropathic pain?

    support, that influence participation and quality of life in people with neuropathic pain? Any explanatory notes(if applicable) Why this...

  27. Relationship between symptoms, cause of neuropathic pain and its treatment:- Is response to pharmacological treatment predicted more reliably by underlying aetiology or by symptom characteristics?

    CG173/2 Question Relationship between symptoms, cause of neuropathic pain and its treatment:- Is response to pharmacological treatment...

  28. Impact of drug-related adverse effects on cost effectiveness and quality of life:- What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain?

    of life in neuropathic pain? Any explanatory notes(if applicable) Why this is important:- Pharmacological agents for neuropathic...

  29. Spinal cord stimulator implantation: Improving theatre efficiency

    availability of beds and workforce challenges” (NHS Improvement 2019). NHS Pain Departments, along with other specialties, struggle for...

  30. Head and neck cancer (QS146)

    This quality standard covers assessing, diagnosing and managing head and neck cancer, including cancer of the upper aerodigestive tract in people aged 16 and over. It describes high-quality care in priority areas for improvement.

  31. NICE encourages further research into percutaneous electrical nerve stimulation (PENS) for refractory neuropathic pain, particularly to provide more information about selection criteria and long-term outcomes, with clear documentation of the indications for treatment.

    into percutaneous electrical nerve stimulation (PENS) for refractory neuropathic pain, particularly to provide more information about...

  32. Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain (MIB305)

    NICE has developed a medtech innovation briefing (MIB) on differential target multiplexed spinal cord stimulation for chronic lower back and leg pain .

  33. For adults with fibromyalgia or persistent treatment-resistant neuropathic pain, what is the clinical and cost effectiveness of cannabidiol (CBD), containing no, or traces of, delta-9-tetrahydrocannabinol (THC), as an add-on to standard treatment?

    For adults with fibromyalgia or persistent treatment-resistant neuropathic pain, what is the clinical and cost effectiveness of...

  34. Spinal metastases and metastatic spinal cord compression (NG234)

    This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.

  35. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  36. Spotlight on valproate prescribing

    also used outside of its product licence (off-label use) for treating neuropathic pain, migraine, depression and dementia. If valproate...

  37. End of life care for infants, children and young people with life-limiting conditions: planning and management (NG61)

    This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.

  38. Aptiva for painful diabetic neuropathy (MIB119)

    NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .

  39. Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain (IPG739)

    Evidence-based recommendations on neurostimulation of lumbar muscles for refractory non-specific chronic low back pain in adults. This involves implanting a pulse generator under the skin of the upper buttock or lower back, which the person can use to manage their pain.

  40. Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain (IPG747)

    Evidence-based recommendations on percutaneous image-guided cryoablation of peripheral neuroma for chronic pain. This involves using a needle-like probe to freeze and destroy small parts of nerves in neuromas to stop the pain signals.

  41. Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (IPG382)

    Evidence-based recommendations on deep brain stimulation for refractory chronic pain syndromes (excluding headache). This involves stimulating a precise area of the brain using an electrode to treat the chronic pain.

  42. Is response to pharmacological treatment predicted more reliably by underlying aetiology or by symptom characteristics?

    symptoms that present in healthcare settings, or whether different neuropathic pain conditions with different aetiologies, respond...

  43. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206)

    This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.

  44. The Integrated Pain and Spinal Service (IPASS): A unique, integrated and collaborative approach to persistent pain management

    assessments and treatments for patients with back and generalised persistent pain. Using a holistic approach the team are able to...

  45. What is the clinical and cost effectiveness of lidocaine patches for localised peripheral pain?

    peripheral pain? Any explanatory notes(if applicable) Source guidance details Comes from guidance Neuropathic pain in...

  46. Stroke rehabilitation in adults (NG236)

    This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.

  47. Patient group directions (MPG2)

    This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.

  48. Laparoscopic uterine nerve ablation (LUNA) for chronic pelvic pain (IPG234)

    Evidence-based recommendations on laparoscopic uterine nerve ablation (LUNA) for chronic pelvic pain. This involves the destruction of a small segment of ligament that carries nerve fibres within the pelvis.

  49. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.